Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Pharma
FDA approves first T-cell therapy for a solid tumor
Iovance priced Amtagvi, a one-time TIL therapy for melanoma, at a wholesale acquisition cost of $515,000 per patient.
Angus Liu
Feb 17, 2024 12:15pm
BMS's Opdivo claims more of the melanoma pie
Oct 16, 2023 11:06am
74% of consumers haven't had a skin exam in past year: DermTech
May 4, 2023 9:15am
Merck and Eisai call it quits on drug combo trial in melanoma
Apr 7, 2023 9:43am
BMS goes double DTC with immunotherapy spots
Jan 25, 2023 7:30am
BMS snares Opdivo melanoma win in eternal struggle with Keytruda
Sep 15, 2022 11:30am